Liver cancer is the sixth most common cancer in the world and the 16th most common in the UK - but it is often detected too ...
Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback